Reference is made to the stock exchange release of 14 May 2018 in which the Board of Directors decided to launch a share option programme of up to 559,852 options. On 2 August 2018 the following employees was granted options in Gentian Diagnostics AS as follows:
Hilja Ibert, CEO of Gentian Diagnostics AS: 139,963 options. Number of options after the grant is 139,963 and number of shares are nil.
Njaal Kind, Group CFO of Gentian Diagnostics AS: 34,991 options. Number of options after the grant is 34,991 and number of shares are nil.
The exercise price for the options granted is NOK 65.24 being the average volume-weighted share price on the Oslo Stock Exchange for the past 10 trading days prior to today. The right to exercise the options is vested over a period of 3 years, with 1/3 of the options vesting by the end of each year as follows:
1/3 of the options granted, no earlier than 2 years after the allocation date
1/3 of the options granted, no earlier than 3 years after the allocation date
1/3 of the options granted, no earlier than 4 years after the allocation date
For further information, please contact: Tomas Settevik, Chairman Cell: +47 90 79 48 25
MeldingsID: 456430 UtstederID: GENT-ME Instrument: GENT-ME Marked: Merkur Market Kategori: MELDEPLIKTIG HANDEL FOR PRIMÆRINNSIDERE Informasjonspliktige opplysninger: Ja